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sUmmary
the world Health organisation  anti-retroviral treatment guidelines  for resource limited 
settings rationalise the recommended standard first and second-line regimens on the 
basis of their efficacy, tolerability, toxicity, availability of fixed-dose combination and 
cost. Boosted protease inhibitors, recommended as second line agents in combination 
with a two drug nucleoside analogue backbone may cause diarrhoea and gastrointestinal 
disturbances and this raises tolerability concerns. Dyslipidaemias and hepatotoxicity 
are also considerable. Ritonavir contributes significantly to these adverse properties. 
We report two patients who had had hepatotoxicity and intractable diarrhoea while on 
a boosted protease inhibitor regimen, treated successfully with unboosted atazanavir in 
combination with two nucleoside analogues. Liver toxicity and diarrhoea resolved,while 
the patients maintained immunological and virological response to the unboosted 
atazanavir based regimen. 
Unboosted atazanavir is an effective option of therapy in patients with suppressed 
viral replication and have ritonavir tolerability and safety challenges. 
case 1
AO, 48 year old female was first seen in our unit three 
years ago with exfoliative erythroderma and jaundice. 
She was taking a Haartregimencomprising 
tenofovir, lamivudine and efavirenz.cd4 + counts 
done during that presentationwas 419/ml. She was 
also on hydrochlorothiazide for hypertension and 
co-trimoxazole prophylaxis.  laboratory examination 
revealed alanine transferase (alt) of 8 x the upper 
limit of normal (Uln) and aSt 40X Uln.  bilirubins, 
alkaline phosphatase, γ gt were all elevated.  inr 
was 1.5 and serum albumin was modestly low. the 
patient had slight pedal oedema and ascites. both 
hepatitis b and c markers were negative. abdominal 
ultrasound scan reported a normal liver.  Haart 
was stopped and restarted after three months when 
transaminases had reduced to less than 3 x Uln. the 
treatment was switched to tenofovir, lamivudine, 
lopinavir/ritonavir on the premise that the hepatits 
in a background of possible liver disease may have 
been efavirenz-associated. the liver transaminases 
rose to x 9 Uln after two weeks of therapy. treatment 
was once more interrupted   and after four weeks of 
serial follow up of transaminases the enzyme levels 
had settled to alt of 1.5 X Uln and aSt 2.5 X Uln. 
at this point ritonavir was considered the potential 
hepatotoxic agent 
 the patient was treated with once daily 
unboosted atazanazvir while maintaining a backbone 
of tenofovir and lamivudine. His cd4 + counts 
continued showing upward trend at 533cp/ml 
while viral loads were undetectable after 6 month 
of therapy.
case 2 
mK was a 39 years old black male who tested 
positive for Hiv infection in december 2008 
following admission to hospital for treatment of 
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severe pneumonia. His cd4 + count were 208/ml. 
viral load assay was not done. He was commenced 
on antiretroviral therapy with a fixed -dose regimen 
containing tenofivir, emtricitabine and efavirenz.
 in march 2009 he was readmitted and treated 
for smear positive pulmonary tuberculosis. He 
completed his tuberculosis therapy successfully while 
maintaining the same Haart regimen.
 He was lost to follow up between September 
2009 and december 2011 when he was seen with 
gastroenteritis and acute kidney injury.  His serum 
chemistry during this admission showed a raised 
creatinine of 946 μmol/l, normal serum transaminases 
and serum amylase levels. Haemoglobin was 15.0gm/
dl with no white cell response. He recorded a cd4+ 
count of 138/ml and Hiv viral load of 100,000copies/
ml thus confirming immunological and virological 
treatment failure.
 the patient improved on rehydration and 
his renal function improved with creatinine levels 
reducing to 225μmol/l. His Hiv regimen was changed 
to abacavir, lamivudine and ritonavir-boosted 
lopinavir and patient was discharged to attend follow 
up as an outpatient.
 eleven days following discharge, mK presented 
back with dysentery and progressive weight loss.
examination revealed bleeding haemorrhoids. His 
haemoglobin was 7.4gm/dl, creatinine 158μmol/l 
and serum potassium reduced to 2.9 mmol/l. 
the patient was treated with blood transfusion, 
potassium replacement, rehydration, daflon and 
rectal suppositories. Patient was discharged on the 
same Haart regimen despite occasional abdominal 
discomfort and diarrhoea.
 at review two months later his viral load was 
undetectable with cd4 + counts of 252/ml.  His weight 
had dropped from 65 kg to 39 kg. liver transminases 
were modestly raised to x2 normal and diarrhoea 
had not resolved. on the basis of poor tolerability 
of boosted protease inhibitor regimen in a patient 
with previous first line treatment failure while on an 
efavirenz-based therapy, the patient was switched to 
unboosted atazanavir 300mg. once, abacavir 300mg. 
twice daily and lamivudine 150mg once daily.
 diarrheoa resolved and patient maintained 
virologic suppression and immunologic reconstitution 
with weight gain to 59 kg in the subsequent six months 
of follow up.
discUssion
the world Health organisation guidelines identify 
the most potent, effective and feasible first-line and 
second-line applicable to the majority of population 
and address the criteria of switching highly active 
antiretroviral therapy (1). the 2013 consolidated 
guidelines on Hiv therapy in treatment naive 
adults and adolescents recommend a fixed-dose 
combinationof tenofovir with either lamivudine or 
emtricitabine and efavirenz as a preferred first-line 
(2, 3). the choice of efavirenz as a preferred nnrti 
over nevirapine is based on its lower propensity to 
cause severe adverse events. compared to nevirapine, 
efavirenz is associated with lower frequency of severe 
hepatotoxicity, skin reaction and hypersensitivity 
reaction (4).
 the second-line treatment recommends use 
of heat-stable fixed-dose combination of ritonavir 
boosted atazanavir orritonavir boosted lopinavir 
as preferred protease inhibitor options (2, 3). the 
recommendations for first and second line therapy 
take cognisnace of efficacy, tolerability, safety and 
option of sequencing therapy. 
 molina et al demonstrated non-inferiority of 
ritonavir boosted atazanavir to ritonavir boosted 
lopinavirboth using a backbone of tenofovir and 
emtricitabine in antiretroviral-naïve patients (5). 
better gastrointestinal tolerability and less metabolic 
toxicity was seen in fixed-dose combination of 
atazanavir a combination that has 100mg. of ritonavir 
as compared to higher ritonavir in other boosted 
protease inhibitor formulations that require 200mg. 
of ritonavir (5). in patients with multiple virologic 
failures boosted atazanavir has been comparable to 
boosted lopinavir in efficacy (6). 
 If ritonavir contributes significantly to toxicity 
and tolerability concerns of use of boosted protease 
inhibitors, then unboosted protease inhibitors 
could be used in patients who are unable to tolerate 
boosted protease inhibitors or in patients who 
manifest toxicities attributable to ritonavir. baril 
et al conducted a meta-analysis of the efficacy and 
safety of unboosted atazanavir compared with 
ritonavir boosted proteaseinhibitor maintenance 
therapy in Hiv-infected adults with established 
virologic suppression. this systematic review of 
randomised controlled trials evaluating the efficacy 
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and safety in patients with established virologic 
suppression upon treatment simplification involving 
the replacement of boosted protease inhibitor with 
unboosted atazanavir found that switching patients 
with virologic suppression from ritonavir boosted 
protease to atazanavir leads to improvement in 
safety without sacrificing virologic efficacy (7). 
The treatment simplification strategy provides for 
improved lipid profiles and overcomes unfavourable 
adverse events like diarrhoea and lipodystrophy (8, 
9, 10). 
 Severe hepatotoxicity has been seen in 5-10% 
of patients on Haart with major risk factors being 
advanced liver disease, hepatitis co-infection and 
elevated liver transaminases at initiation of therapy. 
the dideoxynucleoside analogues stavudine and 
didanosine, nevirapine and tiprinavir and full dose 
ritonavir have been the main culprits (11). Studies 
indicate an association of ritonavir with higher 
rates of severe hepatotoxicity and cholestasis than 
regimens not containing ritonavir (12,13,14) a pilot 
study on the efficacy, pharmacokinetics and safety of 
unboosted atazanavir in patients with end-stage liver 
disease documented no worsening of liver disease. 
Patients in this study were able to gain or maintain 
immunovirological eligibilitywith a limited effect on 
unconjugated bilirubin (15, 16).
 the two case reports illustrate the use of 
unboosted atazanavir in situations where nnrti or 
ritonavir boosted protease inhibitors cannot be used. 
Poor tolerability and associated intractable diarrhoea 
in one patients and severe hepatotoxicity in another 
necessitated withdrawal of ritonavir. both patients 
maintained reasonable immune-reconstitution and 
virologic suppression on a once daily unboosted 
atazanavir therapy.  work done in Senegal on the 
efficacy and safety of unboosted atazanavir in 
combination with two nucleoside analogues conclude 
that with its high genetic barrier of resistance, 
unboosted atazanavir could be valuable alternative 
for nnrti in resource limited countries in some 
Hiv-infected patients where adherence, resistance 
and intolerance to nnrti, and concern for use of 
efavirenz in women with child bearing potential is a 
consideration (17). we must however be quick to point 
out that more data on optimal dosing is still required. 
where treatment with unboosted protease inhibitor 
is considered, care must be taken to use optimal 
doses so as to avoid rapid evolution of resistance. a 
Pharmacokinetic and pharmacodynamic modeling 
of unboosted atazanavir in a cohort of stable Hiv-
infected patients suggest that twice daily dosing may 
optimise drug therapy (18).
 care must be exercised in selecting eligible 
patients. good treatment outcomes are likely if 
patient has virological suppression at the point of 
switch to unboosted atazanavir, have no history of 
previous virologic failure and not on rifampicin based 
tb therapy. both these patients represent switch to 
unboosted atazanavir due to likely ritonavir based 
adverse events.  Simplification studies appear to show 
sustained viral suppression in patients who switch 
to unboosted atazanavir upon viral suppression. it 
is however important to note that current guideline 
recommend boosted protease inhibitor therapy for 
second line treatment in resource limited settings 
and there treatment with unboosted protease 
inhibitors should be limited on to these special 
circumstances.
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